The Drug Resistance and Sensitivity Network (DRSN) is a consortium to conduct collaborative research focused on innovative strategies to understand and combat mechanisms of tumor resistance (intrinsic or acquired) and/or to exploit tumor sensitivity to anti-cancer therapies. The goal of the DRSN is to identify therapeutic targets to overcome drug resistance through studies that determine the mechanisms that lead cancer cells to become resistant to previously effective treatments.
Three working groups have been established to formulate questions underlying basic, translational, clinical and technical knowledge gaps of drug resistance/sensitivity mechanism and to develop approaches to address them through collaboration. All working groups have representatives from each component of the DRSN.
Co Chair: Moshe Sade-Feldman, PhD - Massachusetts General Hospital/Broad
Co-Chair: Evan Lind, PhD - Oregon Health & Science University
Meets on the second Monday of every other month from 1:00-2:00 PM, Eastern Time.
NIH Staff Members
Percy Ivy, MD (NCI)
Lyndsay Harris, MD (NIH/NCI)
Jeffrey Moscow, MD (NIH/NCI)
Beverly Teicher, PhD (NIH)
Bill Timmer, PhD (NIH)
Tami Tamashiro (NCI)
Kim Witherspoon (NCI)
Co-Chair: Cristina Tognon, PhD – Oregon Health & Science University
Co-Chair: Calvin Kuo, MD, PhD - UC San Francisco/Stanford
Meets on the fourth Wednesday of every other month from 1:00-2:00 PM, Eastern Time.
NIH Staff Members
Percy Ivy, MD (NCI)
Lyndsay Harris, MD (NIH/NCI)
Jeffrey Moscow, MD (NIH/NCI)
Beverly Teicher, PhD (NIH)
Bill Timmer, PhD (NIH)
Tami Tamashiro (NCI)
Kim Witherspoon (NCI)
Chair: Keith Flaherty, MD - Massachusetts General Hospital/Broad
NIH Staff Members
Percy Ivy, MD (NCI)
Lyndsay Harris, MD (NIH/NCI)
Jeffrey Moscow, MD (NIH/NCI)
Beverly Teicher, PhD (NIH)
Bill Timmer, PhD (NIH)
Tami Tamashiro (NCI)
Kim Witherspoon (NCI)
